Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

NCT00472290 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00472290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00472290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
Lead sponsor
Amgen
Phase
Not applicable
Overall status
Completed
Start date
April 1, 2007
Completion date
December 26, 2011
Enrollment
72 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hematology, mds, myelodysplastic syndromes, thrombocytopenia